Suppr超能文献

新辅助吉西他滨联合卡铂治疗肌层浸润性膀胱癌(包括不能耐受顺铂者)后即刻行膀胱切除术的疗效和安全性:一项前瞻性单臂研究。

Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.

机构信息

Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifucho, Hirosaki, 036-8562, Japan.

出版信息

Int J Clin Oncol. 2013 Aug;18(4):724-30. doi: 10.1007/s10147-012-0447-z. Epub 2012 Jul 19.

Abstract

BACKGROUND

Neoadjuvant cisplatin-based chemotherapy for patients with muscle-invasive bladder cancer (BC) has better survival benefit than radical cystectomy (RC) alone. However, optimal dosing schedule, including drug selection, number of cycles, and interval between chemotherapy and cystectomy, as well as acceptable regimens remain to be established. We conducted a single-arm prospective study to evaluate efficacy and safety of neoadjuvant gemcitabine plus carboplatin (GCarbo) chemotherapy followed by immediate RC in patients with muscle-invasive BC, including cisplatin-unfit patients.

METHODS

Between March 2005 and June 2011, we enrolled 116 patients with histologically proven muscle-invasive BC, including 44 % of the patients who were identified as cisplatin-unfit. All participants received two courses of GCarbo therapy, gemcitabine 800 mg/m(2) administered on days 1, 8, and 15 and carboplatin with an area under the curve of four (AUC 4) administered on day 2. RC and bilateral pelvic lymphadenectomy were performed approximately within a month after cessation of chemotherapy. The primary endpoint was pT0 in the cystectomy specimen. Secondary endpoints were overall response rate, overall (OS) and disease-free survival (DFS), and toxicity. Survival after cystectomy was analyzed using the Kaplan-Meier method.

RESULTS

The RC specimens of 28 (24.1 %) patients showed pT0. At a median follow-up period of 41 months, the OS and DFS rates were 89.7 and 86.3 %, respectively. No patients had grade 3/4 gastrointestinal toxicity or renal impairment.

CONCLUSIONS

Neoadjuvant GCarbo therapy followed by immediate RC is safe, even in cisplatin-unfit patients, and provides a favorable pathological cancer-free state. The single-arm single-institution study design and relatively short observation period were limitations of this study.

摘要

背景

新辅助顺铂为基础的化疗治疗肌层浸润性膀胱癌(BC)患者比单纯根治性膀胱切除术(RC)有更好的生存获益。然而,最佳的剂量方案,包括药物选择、化疗周期数、化疗与 RC 之间的间隔,以及可接受的方案仍有待建立。我们进行了一项单臂前瞻性研究,评估新辅助吉西他滨联合卡铂(GCarbo)化疗后立即行 RC 治疗肌层浸润性 BC 患者(包括顺铂不适合的患者)的疗效和安全性。

方法

2005 年 3 月至 2011 年 6 月,我们纳入了 116 例经组织学证实的肌层浸润性 BC 患者,其中 44%的患者被认为是顺铂不适合的患者。所有患者均接受了两个疗程的 GCarbo 治疗,吉西他滨 800mg/m²,第 1、8 和 15 天给药,卡铂 AUC4,第 2 天给药。化疗结束后约一个月内进行 RC 和双侧盆腔淋巴结清扫术。主要终点是 RC 标本中的 pT0。次要终点是总缓解率、总生存期(OS)和无病生存期(DFS)以及毒性。采用 Kaplan-Meier 法分析 RC 后的生存情况。

结果

28 例(24.1%)患者的 RC 标本显示 pT0。中位随访 41 个月时,OS 和 DFS 率分别为 89.7%和 86.3%。无患者出现 3/4 级胃肠道毒性或肾功能损害。

结论

新辅助 GCarbo 治疗后立即行 RC 是安全的,即使是在顺铂不适合的患者中,也能提供良好的病理无癌状态。本研究的局限性在于单臂单中心研究设计和相对较短的观察期。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验